A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab.


Journal

Dermatology online journal
ISSN: 1087-2108
Titre abrégé: Dermatol Online J
Pays: United States
ID NLM: 9610776

Informations de publication

Date de publication:
15 Mar 2020
Historique:
received: 01 05 2020
accepted: 01 05 2020
entrez: 2 7 2020
pubmed: 2 7 2020
medline: 11 7 2020
Statut: epublish

Résumé

Pityriasis rubra pilaris is a rare psoriasiform dermatitis. Treatment has been adopted from psoriasis protocols, with topical corticosteroids and systemic retinoids as first-line agents, followed by escalation to biologics for recalcitrant disease. We report a patient with resistant pityriasis rubra pilaris who dramatically improved with acitretin and ustekinumab, a combination not well documented in the literature. The purpose of this letter is to emphasize the potential benefit of dual therapy in patients who fail traditional pityriasis rubra pilaris treatment regimens.

Identifiants

pubmed: 32609453
pii:

Substances chimiques

Dermatologic Agents 0
Keratolytic Agents 0
Ustekinumab FU77B4U5Z0
Acitretin LCH760E9T7

Types de publication

Case Reports Letter

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Elizabeth Cook (E)

School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX. ttuhsc2020@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH